SCHEMBL25260720

SCHEMBL25260720

Nc1nc2ccc(Oc3ccc(Br)cn3)cc2s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.57
TP53 P04637 3/20 0.57
NPC1 O15118 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 2/20 0.57
HTT P42858 2/20 0.57
CYP3A4 P08684 5/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C19 P33261 1/20 0.54
HSD17B10 Q99714 2/20 0.53
ALDH1A1 P00352 1/20 0.53
TSHR P16473 1/20 0.53
PIK3CD O00329 6/20 0.51
PIK3CA P42336 6/20 0.51
PIK3CB P42338 6/20 0.51
PI4KA P42356 6/20 0.51
PIK3CG P48736 6/20 0.51
PI4KB Q9UBF8 6/20 0.51
PIP5K1C O60331 1/20 0.51
GAA P10253 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31114515 1.00 RAB9A (0.57) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL17050820 0.84 TDP1 (0.57) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL30450378 0.81 SCN4A (0.60) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL25257398 0.81 SCN4A (0.60) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL20568080 0.80 RAB9A (0.84) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL21186288 0.79 RAB9A (0.57) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL21186210 0.78 RAB9A (0.68) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL14024770 0.77 RAB9A (0.62) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL105971 0.75 RAB9A (0.61) RAB9ATP53NPC1SMN1; SMN2MAPT
SCHEMBL21186207 0.75 RAB9A (0.70) RAB9ATP53NPC1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
EP-4460500-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) 2024-11-13 EP disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 RAB9A 2727/4885TP53 1893/4885NPC1 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.